Tempest Therapeutics names Nicholas Rossettos as new CFO

Tempest Therapeutics, Inc. disclosed in an 8-K dated August 18, 2026 that Justin Trojanowski notified the company of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer, and from any other positions he holds with the company, effective September 1, 2026.¹

The company's board responded by appointing a successor. Effective September 1, 2026, the board appointed Nicholas Rossettos as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the company.¹

Rossettos brings a mix of advisory and interim finance roles at other companies. Before joining Tempest, Rossettos, 60, had served since April 2025 as a financial advisor to TransCode Therapeutics, Inc. (Nasdaq: RNAZ), and from March 2024 to October 2024 as interim Chief Financial Officer of Sernova Corp. (TSX: SVA), described as a clinical-stage biotechnology company.¹ He has also worked since 2012 as a consulting chief financial officer for emerging and growth-stage businesses, including in a fractional CFO role with Charles River CFO.¹ Earlier, he served as Chief Financial Officer of Egenix, Inc., described as an early-stage cancer therapy startup, from 2006 to 2012.¹

Tempest's filing notes his academic background: Rossettos is a certified public accountant who earned an A.B. in Economics from Princeton University and an M.B.A. in Accounting from Northeastern University.¹

The filing states Rossettos will enter into the company's standard form of indemnification agreement, previously filed by the company.¹ It also states there are no family relationships between Rossettos and any of the company's directors or executive officers, and no arrangements or understandings tied to his appointment.¹ Additionally, there are no transactions involving Rossettos requiring disclosure under Item 404(a) of Regulation S-K.¹ The 8-K was signed by CEO Matthew Angel on August 24, 2026.